Prostate cancer immunotherapy: the path forward

被引：7
作者：
Madan, Ravi A. [1 ]
Gulley, James L. [1 ]
机构：
[1] NCI, Genitourinary Malignancies Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA
来源：
CURRENT OPINION IN SUPPORTIVE AND PALLIATIVE CARE | 2017年 / 11卷 / 03期
关键词：
cancer vaccines; immune checkpoints; immunotherapy; prostate cancer; SIPULEUCEL-T; DOUBLE-BLIND; CELLULAR IMMUNOTHERAPY; TARGETED IMMUNOTHERAPY; IMMUNE CHECKPOINT; TUMOR-CELLS; VACCINE; IPILIMUMAB; SURVIVAL; ANTIGEN;
D O I：
10.1097/SPC.0000000000000278
中图分类号：
R19 [保健组织与事业（卫生事业管理）];
学科分类号：
摘要：
Purpose of review To provide an overview of current strategies being investigated in the development of immunotherapy in prostate cancer. Recent findings Development of immunotherapy in prostate cancer actually began in 2010 with FDA approval of sipuleucel-T. Given that immune checkpoint inhibitor trials have either been negative at the phase III level or underwhelming in smaller studies, it is likely that combination strategies will be required to further maximize the impact immune-based therapies on the clinical course of the disease. Emerging data suggests the presence of multiple checkpoint inhibitors in the prostate cancer tumor microenvironment highlighting the need for combination immunotherapy platforms that would potentially include androgen deprivation, chemotherapy, or radiation. Summary Preclinical and clinical data support immune-based combinations in prostate cancer and several trials are underway to better define the future of immunotherapy in prostate cancer.
引用
收藏
页码：225 / 230
页数：6
相关论文
共 34 条
  • [1] Randomized, Double-Blind, Phase III Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naive Castration-Resistant Prostate Cancer
    Beer, Tomasz M.
    Kwon, Eugene D.
    Drake, Charles G.
    Fizazi, Karim
    Logothetis, Christopher
    Gravis, Gwenaelle
    Ganju, Vinod
    Polikoff, Jonathan
    Saad, Fred
    Humanski, Piotr
    Piulats, Josep M.
    Gonzalez Mella, Pablo
    Ng, Siobhan S.
    Jaeger, Dirk
    Parnis, Francis X.
    Franke, Fabio A.
    Puente, Javier
    Carvajal, Roman
    Sengelov, Lisa
    McHenry, M. Brent
    Varma, Arvind
    van den Eertwegh, Alfonsus J.
    Gerritsen, Winald
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (01) : 40 - +
  • [2] Randomized Trial of Autologous Cellular Immunotherapy with Sipuleucel-T in Androgen-Dependent Prostate Cancer
    Beer, Tomasz M.
    Bernstein, Guy T.
    Corman, John M.
    Glode, L. Michael
    Hall, Simon J.
    Poll, Wayne L.
    Schellhammer, Paul F.
    Jones, Lori A.
    Xu, Yi
    Kylstra, Jelle W.
    Frohlich, Mark W.
    [J]. CLINICAL CANCER RESEARCH, 2011, 17 (13) : 4558 - 4567
  • [3] The use of chelated radionuclide (samarium-153-ethylenediaminetetramethylenephosphonate) to modulate phenotype of tumor cells and enhance T cell-mediated killing
    Chakraborty, Mala
    Wansley, Elizabeth K.
    Carrasquillo, Jorge A.
    Yu, Sarah
    Paik, Chang H.
    Camphausen, Kevin
    Becker, Michael D.
    Goeckeler, William F.
    Schlom, Jeffrey
    Hodge, James W.
    [J]. CLINICAL CANCER RESEARCH, 2008, 14 (13) : 4241 - 4249
  • [4] A National Multicenter Phase 2 Study of Prostate-specific Antigen (PSA) Pox Virus Vaccine with Sequential Androgen Ablation Therapy in Patients with PSA Progression: ECOG 9802
    DiPaola, Robert S.
    Chen, Yu-Hui
    Bubley, Glenn J.
    Stein, Mark N.
    Hahn, Noah M.
    Carducci, Michael A.
    Lattime, Edmund C.
    Gulley, James L.
    Arlen, Philip M.
    Butterfield, Lisa H.
    Wilding, George
    [J]. EUROPEAN UROLOGY, 2015, 68 (03) : 365 - 371
  • [5] Androgen ablation mitigates tolerance to a prostate/prostate cancer-restricted antigen
    Drake, CG
    Doody, ADH
    Mihalyo, MA
    Huang, CT
    Kelleher, E
    Ravi, S
    Hipkiss, EL
    Flies, DB
    Kennedy, EP
    Long, MX
    McGary, PW
    Coryell, L
    Nelson, WG
    Pardoll, DM
    Adler, AJ
    [J]. CANCER CELL, 2005, 7 (03) : 239 - 249
  • [6] Activated Lymphocyte Recruitment Into the Tumor Microenvironment Following Preoperative Sipuleucel-T for Localized Prostate Cancer
    Fong, Lawrence
    Carroll, Peter
    Weinberg, Vivian
    Chan, Stephen
    Lewis, Jera
    Corman, John
    Amling, Christopher L.
    Stephenson, Robert A.
    Simko, Jeffrey
    Sheikh, Nadeem A.
    Sims, Robert B.
    Frohlich, Mark W.
    Small, Eric J.
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2014, 106 (11):
  • [7] VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer
    Gao, Jianjun
    Ward, John F.
    Pettaway, Curtis A.
    Shi, Lewis Z.
    Subudhi, Sumit K.
    Vence, Luis M.
    Zhao, Hao
    Chen, Jianfeng
    Chen, Hong
    Efstathiou, Eleni
    Troncoso, Patricia
    Allison, James P.
    Logothetis, Christopher J.
    Wistuba, Ignacio I.
    Sepulveda, Manuel A.
    Sun, Jingjing
    Wargo, Jennifer
    Blando, Jorge
    Sharma, Padmanee
    [J]. NATURE MEDICINE, 2017, 23 (05) : 551 - +
  • [8] Combination of docetaxel and recombinant vaccine enhances T-Cell responses and antitumor activity: Effects of docetaxel on immune enhancement
    Garnett, Charlie T.
    Schlom, Jeffrey
    Hodge, James W.
    [J]. CLINICAL CANCER RESEARCH, 2008, 14 (11) : 3536 - 3544
  • [9] Early evidence of anti-PD-1 activity in enzalutamide-resistant prostate cancer
    Graff, Julie N.
    Alumkal, Joshi J.
    Drake, Charles G.
    Thomas, George V.
    Redmond, William L.
    Farhad, Mohammad
    Cetnar, Jeremy P.
    Ey, Frederick S.
    Bergan, Raymond C.
    Slottke, Rachel
    Beer, Tomasz M.
    [J]. ONCOTARGET, 2016, 7 (33) : 52810 - 52817
  • [10] Role of Antigen Spread and Distinctive Characteristics of Immunotherapy in Cancer Treatment
    Gulley, James L.
    Madan, Ravi A.
    Pachynski, Russell
    Mulders, Peter
    Sheikh, Nadeem A.
    Trager, James
    Drake, Charles G.
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2017, 109 (04):
1234